The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > BUSINESS
BUSINESS
- Actelion Receives Approval for Generic Version of Flolan
February 22, 2013
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
- No Statistical Significance Shown in OS between Tivozanib and Sorafenib in PIII Study: Astellas
February 18, 2013
- Nihon Medi-Physics to Establish New Manufacturing Base for PET Diagnostics in Fujioka City, Gunma Prefecture
February 18, 2013
- Small and Medium Sized Pharmacies Jointly Buys Generics Directly from Manufacturers
February 15, 2013
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
- AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
- Allegra, Allelock Face Stiff Competition from Generics in Anti-Allergic Drug Market
February 14, 2013
- Otsuka Holdings Pharmaceutical Sales Up 3.4% in April-December Thanks to Abilify Sales Hike
February 14, 2013
- Samsca 7.5 mg Tablets Approved: Otsuka
February 14, 2013
- Novartis Will Explain to Doctors that 2009 Article on Diovan Is Invalid: President Mitani
February 13, 2013
- Bristol-Myers, Pfizer Underline Eliquis’s Superiority vs. Warfarin
February 13, 2013
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…